Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander?

被引：228

作者：

Tsouli, Sofia G.

Liberopoulos, Evangelos N.

Mikhailidis, Dimitri P.

Athyros, Vasihos G.

Elisaf, Moses S. ^{[1
]}

机构：

[1] Univ Ioannina, Sch Med, Dept Internal Med, GR-45110 Ioannina, Greece

[2] Univ London, Dept Clin Biochem, Vasc Dis Prevent Clin,Royal Free & Univ Coll, Royal Free Hosp,Med Sch, London NW3 2QG, England

[3] Aristotle Univ Thessaloniki, Hipocrat Hosp, Atherosclerosis Unit, Thessaloniki 54642, Greece

来源：

METABOLISM-CLINICAL AND EXPERIMENTAL | 2006年 / 55卷 / 10期

关键词：

D O I：

10.1016/j.metabol.2006.05.013

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Elevated serum uric acid (SUA) levels are commonly seen in patients with the metabolic syndrome (MetS). Several mechanisms, both direct and indirect, connect the increased SUA levels with the established diagnostic criteria of MetS. It is possible that the increased cardiovascular disease risk associated with the MetS is partially attributed to elevated circulating SUA concentration. Several drugs used in the treatment of MetS may alter SUA levels. Thus, lifestyle measures together with the judicious selection of drugs for the treatment of hypertension, dyslipidemia, and insulin resistance associated with MetS may result in a reduction of SUA levels and possibly cardiovascular disease risk. This review summarizes the pathophysiologic association between SUA and MetS and focuses on the prevention of hyperuricemia and its cardiovascular consequences. (c) 2006 Elsevier Inc. All rights reserved.

引用

页码：1293 / 1301

页数：9

共 175 条

[1] Ascorbate prevents prooxidant effects of urate in oxidation of human low density lipoprotein [J].